| Date | Form | Description | Docs | XBRL | Pages |
| 09/09/05 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
25 | |
| 06/09/05 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
22 | |
| 05/02/05 | UPLOAD | SEC-generated letter |
|
1 | |
| 04/22/05 | 10-K/A | Annual report pursuant to section 13 and 15(d) |
|
13 | |
| 04/15/05 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
2 | |
| 04/01/05 | UPLOAD | SEC-generated letter |
|
3 | |
| 03/11/05 | SC 13D/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
3 | |
| 03/11/05 | SC 13D/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
3 | |
| 03/10/05 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
24 | |
| 02/23/05 | 4 | Statement of changes in beneficial ownership of securities |
|
1 |
Latest News & Events
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
Read More...Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Read More...Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
Read More...